AP
PRAX icon

Aspect Partners’s Praxis Precision Medicines PRAX Stock Holding History

Aspect Partners’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-47
Closed -$13.9K – 734
2025
Q4 		$13.9K Buy
+47
New +$8.75K 0.01% 228

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Aspect Partners's PRAX Position: Q1 2026 in Review

Aspect Partners sold out of Praxis Precision Medicines (PRAX) in Q1 2026, closing a stake of 47 shares — an estimated $13.9K sold.

Aspect Partners first reported a position in PRAX in Q4 2025 and held it in 1 quarter. The position peaked at $13.9K in Q4 2025. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

  • Aspect Partners reported no remaining Praxis Precision Medicines position as of Q1 2026 after selling out during the quarter.
  • Aspect Partners sold 47 Praxis Precision Medicines shares in Q1 2026, an estimated $13.9K.
  • Aspect Partners first reported a position in Praxis Precision Medicines in Q4 2025 and held it in 1 quarter.
  • Aspect Partners's Praxis Precision Medicines position peaked at $13.9K in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Aspect Partners's 13F filing for Q1 2026, filed 2 Apr 2026.